This presentation highlights the challenges of emerging and re-emerging infectious diseases such as MTB, HIV, MRSA, and Ebola.
This presentation also provides case studies on how innovative technologies like NGS are utilized to provide a deeper understanding of the pathogen and drug resistance pathways and thus provide better insights into developing diagnostics and therapies that are efficacious against the target pathogen and its resistant variants with improved safety. Download the presentation to learn more about the challenge of emerging infectious diseases.
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
